Candel Therapeutics, Inc.
CADL
$4.95
-$0.10-1.89%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 42.19% | 40.60% | 16.57% | 8.20% | 8.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.38% | 50.82% | 30.40% | 2.89% | -18.41% |
| Operating Income | -94.38% | -50.82% | -30.40% | -2.89% | 18.41% |
| Income Before Tax | -109.59% | -5.85% | 78.43% | 189.76% | -26.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -109.59% | -5.85% | 78.43% | 189.76% | -26.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.59% | -5.85% | 78.43% | 189.76% | -26.84% |
| EBIT | -94.38% | -50.82% | -30.40% | -2.89% | 18.41% |
| EBITDA | -98.37% | -52.87% | -31.40% | -3.06% | 18.84% |
| EPS Basic | -35.78% | 38.26% | 87.49% | 151.92% | -3.37% |
| Normalized Basic EPS | -36.13% | 38.26% | 87.49% | 151.93% | -6.80% |
| EPS Diluted | -35.78% | 38.26% | 87.49% | 146.16% | -3.37% |
| Normalized Diluted EPS | -36.13% | 38.26% | 87.49% | 147.84% | -6.80% |
| Average Basic Shares Outstanding | 54.36% | 71.47% | 72.33% | 72.90% | 22.71% |
| Average Diluted Shares Outstanding | 54.36% | 71.47% | 72.33% | 87.57% | 22.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |